Concepedia

Shalu Pahuja

SP

Statistics

Publications

6

Citations

165

H-Index

6

Active since

2014

Affiliations

UPMC Hillman Cancer Center(Current)

University of Pittsburgh

Penn State Milton S. Hershey Medical Center

University of Pittsburgh Medical Center

Magee-Womens Hospital

Shalu Pahuja is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and cancer pharmacology.

Publications per year

2014–2022

6

Publications

6

Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

Shannon Puhalla, Jan H. Beumer, Shalu Pahuja et al. · Journal of Clinical Oncology · 2014 · 62 citations

, , +17

A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).

Shalu Pahuja, Jan H. Beumer, Leonard J. Appleman et al. · Journal of Clinical Oncology · 2015 · 29 citations

, , +17

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

Thomas J. George, Greg Yothers, Samuel A. Jacobs et al. · Journal of Clinical Oncology · 2022 · 28 citations

, , +17

Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).

Shalu Pahuja, Jan H. Beumer, Leonard J. Appleman et al. · Journal of Clinical Oncology · 2014 · 20 citations

, , +17

Preliminary activity of veliparib (V) in <i>BRCA2</i>-mutated metastatic castration-resistant prostate cancer (mCRPC).

Shalu Pahuja, Leonard J. Appleman, Chandra P. Belani et al. · Journal of Clinical Oncology · 2015 · 16 citations

, , +16

1–5 of 6